Abstract: PO2442
Transplantation of Kidneys from Hepatitis C-Infected Donors to Hepatitis C-Negative Recipients: 1-Year Renal Allograft Outcomes
Session Information
- Transplant Complications: Infection
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 1902 Transplantation: Clinical
Authors
- Molnar, Miklos Zsolt, Methodist University Hospital, Memphis, Tennessee, United States
- Azhar, Ambreen, Methodist University Hospital, Memphis, Tennessee, United States
- Tsujita, Makoto, Methodist University Hospital, Memphis, Tennessee, United States
- Talwar, Manish, Methodist University Hospital, Memphis, Tennessee, United States
- Balaraman, Vasanthi, Methodist University Hospital, Memphis, Tennessee, United States
- Bhalla, Anshul, Methodist University Hospital, Memphis, Tennessee, United States
- Kovesdy, Csaba P., The University of Tennessee Health Science Center, Memphis, Tennessee, United States
- Nair, Satheesh P., Methodist University Hospital, Memphis, Tennessee, United States
- Eason, James D., Methodist University Hospital, Memphis, Tennessee, United States
Group or Team Name
- Methodist Transplant Epidemiology Research Group
Background
Transplant centers in United States are increasingly willing to transplant kidneys from hepatitis C (HCV) infected donors to hepatitis C negative recipients. Long-term renal outcome data of a non-prophylactic HCV treatment approach outside clinical trials is missing.
Methods
We examined 65 HCV negative recipients who received a HCV infected kidney transplant (HCV+) and 59 HCV negative recipients who received a HCV non-infected kidney transplant (HCV-) during 2018 in a single transplant center. We compared estimated glomerular filtration rate (eGFR), cumulative results of per-cause and surveillance protocol biopsies, development of de novo donor specific antibodies (DSAs), co-infection rates and patient and graft outcomes up to 1 year post-transplant between HCV+ versus HCV- groups.
Results
The mean±SD age of recipients was 52±11 years, 43% were female, 19% and 80% of recipients were Caucasian and African-American, respectively. Baseline characteristics were similar between the HCV+ and HCV- groups. The delayed graft function rate, estimated GFRs at post-transplant 3, 6, 9 and 12 months, cumulative rejection rate, development of de novo DSAs and co-infection rates were not statistically significantly different between the HCV+ and HCV- groups (Table).
Conclusion
Recipients of HCV-viremic kidneys have similar renal allograft function, incidence of rejection in the first year after transplantation compared to those who received HCV-non-viremic kidneys.
Renal graft and patient outcome of all kidney transplant recipients
| Entire Cohort | HCV+ | HCV- | p-value | |
| Observations (n) | 124 | 65 | 59 | N/A |
| Delayed Graft Function, N, (%) | 12 (10%) | 5 (12%) | 7 (8%) | 0.43 |
| Estimated GFR at 3 months after transplantation (ml/min/1.73m2), mean (SD) | 63 (20) | 63 (18) | 64 (21) | 0.85 |
| Estimated GFR at 6 months after transplantation (ml/min/1.73m2), mean (SD) | 66 (19) | 66 (18) | 66 (21) | 0.96 |
| Estimated GFR at 9 months after transplantation (ml/min/1.73m2), mean (SD) | 67 (18) | 66 (15) | 67 (20) | 0.62 |
| Estimated GFR at 12 months after transplantation (ml/min/1.73m2), mean (SD) | 66 (19) | 64 (16) | 66 (22) | 0.69 |
| ACR/ABMR (N of patient / N of patients with biopsy result (%)) | 26/113 (23%) | 13/54 (24%) | 13/59 (22%) | 0.80 |
| De novo DSA (N of patient / N of patients with DSA result (%)) | 26/94 (28%) | 20/64 (31%) | 6/30 (20%) | 0.26 |
| BK viremia (>10,000 copies) (N (%)) | 19 (16%) | 12 (18%) | 7 (13%) | 0.42 |
| CMV viremia (>1,000 copies) (N (%)) | 15 (12%) | 11 (17%) | 4 (7%) | 0.10 |
| Death (N (%)) | 4 (3%) | 1 (2%) | 3 (5%) | 0.26 |
| Graft Loss (including death) (N (%)) | 7 (6%) | 1 (2%) | 6 (10%) | 0.04 |